lrn.peerview.com
May 30, 2025, 05:42
Colorectal Cancer Alliance and PeerView Live at ASCO 2025 on Systemic Therapy Regimens in CRC
Colorectal Cancer Alliance shared a post on LinkedIn:
“The Colorectal Cancer (CRC) treatment landscape has undergone a profound transformation with advances in immune-based therapies tailored to patient-specific factors. Molecular profiling, like MSI/MMR and POLE/POLD1 testing, is now key in guiding precision treatment.
Immunotherapy’s success in MSI-H/dMMR CRC has led to its approval for metastatic cases and expanded use in earlier stages. GI-oncology clinicians are crucial in delivering personalized, effective CRC care. Have you redefined your care strategies?
Join the Colorectal Cancer Alliance and PeerView Live at ASCO 2025 to explore how experts are adapting systemic therapy regimens in CRC. This event will cover the current recommendations for molecular testing, the latest data supporting immunotherapy platforms, and provide new strategies to develop individualized treatment plans using team-based strategies that address practical aspects of care. Register for this live in-person and virtual MedEd event on May 30 at 6:30 PM CDT.
This activity is supported by independent educational grants from Bristol Myers Squibb and GSK.”
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 9, 2025, 14:14